Learn More
The adverse event (AE) profiles of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) agents are of great interest, in particular the most recently approved statin, rosuvastatin. The forwarding of reports of AEs has been shown to be influenced by several reporting biases, including secular trend, the new drug reporting effect,(More)
Some industry observers and medical professionals, and even the popular media, assert that pharmaceutical companies are conducting an increasing number of clinical trials in countries outside the more established geographies of North America and Western Europe as a way to minimize costs, speed clinical trial completion and reduce regulatory oversight. This(More)
  • 1